Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer




[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development



[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

DBT smartphone app implemented by private clinic in Denmark

DBT smartphone app implemented by private clinic in Denmark

DBT smartphone app by Monsenso will be implemented by the end of August

Copenhagen, Denmark – 18 July 2017 Monsenso, a Danish developer in mobile health solutions for mental health, has announced that Datlinien, a private clinic in Denmark, will soon implement the Monsenso mHealth solution with an added Dialectical Behavioural Therapy (DBT) module.
DBT is an evidence-based treatment that is commonly used to treat Borderline Personality Disorder.

Online-based DBT solutions have been found to make treatment easier to manage for clinicians, by storing information in an easily accessible place through cloud technology.

A new DBT module was recently added to the Monsenso mHealth solution as part of the mDiary Study, a research project done in collaboration with several Danish partners. The Monsenso mHealth solution, which consists of a smartphone app for individuals and a web portal for clinicians, provides a reliable, efficient, and clinically-validated smartphone based approach to DBT.

Some of the key factors of DBT include skills training and self-monitoring, which have been administered traditionally through paper-based self-assessments, workbooks and diaries. The Monsenso DBT smartphone app helps optimise and organise this process, by putting self-assessments, self-monitoring, skills training, emotion rating, and synchronized clinician feedback into one convenient location – your smartphone.

Datlinien offers mental health services, with a special focus on DBT, to public and private institutions, and they provide DBT treatment for both group and individual therapy.

Thomas Lethenborg, CEO at Monsenso, said “This new DBT module was developed as part of the mDiary Study to complement the treatment of individuals undergoing DBT treatment. It was designed to modernise the traditionally used paper-based assessments and skills training, and to make it more intuitive.”

Dr. Shahram Elahi Panah, General Manager of Datlinien, said “By adopting this new technology, we want to raise the bar on the mental health services offered by private clinics in Denmark. The Monsenso DBT smartphone app makes data collection and skills training more fun and interactive, which is great for the patients because it increases compliance and engagement. On the other hand, it is also great for us, the clinicians, because we can visualise all the patient data more easily.”

Click on the link to read the press release in Danish.

For additional information contact:

Helen Chen
+45 30 25 15 26